Home
NewsNewsCSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
On March 5, 2026, CSG.BIO, which is a global life sciences and healthcare platform with services across fertility, reproductive health, and biologic preservation, as well as family-building, went ahead with the acquisition of Hanabusa IVF, Asian Egg Bank.
Hanabusa IVF, which is based in San Diego, California, is known for its customised fertility care, which includes its unique approach when it comes to mini-IVF along with lower-stimulation treatments. Asian Egg Bank is now one of the leading options for intended parents and fertility clinics to find Asian donor eggs. The two groups together give CSG.BIO a strong platform for reproductive care and donor eggs that is becoming more important in the US and around the world.
The acquisition of Hanabusa IVF, Asian Egg Bank, adds to the present speciality IVF practice of CSG.BIO, the New England Fertility Institute in Stamford, Connecticut. It turns CSG.BIO into a world leader when it comes to reproductive medicine, with cutting-edge clinics located near major domestic as well as international gateways on both coasts. This next phase helps Hanabusa IVF and New England Fertility Institute work together toward a bigger long-term goal – making personalised fertility care more available, establishing internationally connected surrogacy along with third-party reproduction services, and continuing to expand their specialised mini-IVF offering within the large global network of CSG.BIO.
It is well to be noted that the strategic fit is just as crucial to the Asian Egg Bank. Other organisations in the group include CryoChoice and AlphaCord, as well as CellSave. This kind of sync creates real synergy between family-building support and biologic storage along with reproductive services, and it also makes the infrastructure much stronger when it comes to future growth.
“Joining CSG.BIO gives us the opportunity to build on what makes Hanabusa IVF and Asian Egg Bank so distinctive while gaining the strength of a broader global platform,” said Peter Fuzesi, CEO of Hanabusa IVF and Asian Egg Bank. “We see strong alignment between our mission and CSG.BIO’s capabilities across fertility, preservation, and family-building services. This next step allows us to continue advancing personalised care in San Diego while expanding what we can offer patients, intended parents, and partners around the world.”
“We are thrilled to welcome Hanabusa IVF and Asian Egg Bank into the CSG.BIO family,” said Sarah Al-Hajali, CEO of CSG.BIO. “Hanabusa IVF has built an exceptional reputation for thoughtful, patient-centred fertility care, and Asian Egg Bank adds an important and highly specialised donor egg platform to our growing organisation. Together, these additions strengthen our vision for the future of reproductive medicine, family building, and biologic preservation, and we are excited for what lies ahead.”
Provident Healthcare Partners gave Hanabusa IVF and Asian Egg Bank advice on the transaction by helping it go through. Corbel Capital Partners, an independent investment firm that is based in Los Angeles that executes customised structured debt or equity investments in lower-market businesses and works with management to create value, provided the financing for the deal.
Fertility care leader IVI RMA North America announces a new partnership with Island Reproductive Services
Overture Life’s DaVitri fertility automation platform gains CE Mark, paving the way for wider IVF and egg freezing access in Europe.
Simbryo Technologies introduces the Simbryo FX personalized assay, a diagnostic test that measures endometrial fertility to predict embryo implantation success and improve IVF outcomes with more than 90% specificity.
Technology-Enabled Cryostorage is transforming fertility storage as Reprotech and TMRW combine expertise in digital specimen management and biorepository services. The partnership enhances scalability, safety, and efficiency while supporting clinics with advanced solutions. This strategic move positions the combined company to lead innovation and meet growing global demand in cryostorage services.
CDSCO Orders on IVF Medical Devices reinforce strict regulatory oversight across India’s fertility sector. The directive mandates licensing compliance under existing laws, ensuring IVF and ART devices meet safety and quality standards. This move aims to curb unauthorized sales, strengthen enforcement, and bring greater accountability to medical device usage in reproductive healthcare.
The Tennessee State Law could change how the embryos are handled at the time of treatment, thereby making the IVF clinic services in the state more expensive for patients seeking fertility care.
Before taking a call on IVF, survey conducted in the U.S., UK, Ireland, and Canada suggests that people are looking for complete & less expensive options to treat root causes of infertility.
